Drug
Bdc 4182
Bdc 4182: highest development phase Phase 1/2, developed by Bolt Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Bolt Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| BDC-4182 NCT06921837 | Phase 1/2 | Gastric Cancer Adenocarcinoma Metastatic |
Latest
No recent events.
Follow Bdc 4182 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.